Ga-68-PSMA PET/CT对根治性前列腺切除术后极早期生化复发患者管理的影响
该回顾性研究纳入28例根治性前列腺切除术后极早期生化复发(PSA<0.5 ng/ml)患者,评估PSMA-PET/CT的检测率及对管理的影响。结果显示PSMA-PET/CT阳性率为60.7%,42.8%患者的管理决策发生改变,多数阳性患者病灶少于3个。
要点
- 极早期生化复发(PSA<0.5 ng/ml)患者PSMA-PET/CT阳性率达60.7%。
- 42.8%患者因PSMA-PET/CT结果改变管理决策,多涉及挽救性放疗或系统治疗。
- 阳性患者中仅1例为多转移,其余为床区复发或寡转移。
核心结论
- PSMA-PET/CT在根治性前列腺切除术后极早期生化复发(PSA<0.5 ng/ml)中具有高检测率,且多数阳性患者病灶少于3个,可能影响挽救性治疗选择。
研究设计与样本
- 回顾性研究,纳入28例根治性前列腺切除术后极早期生化复发(PSA<0.5 ng/ml)并接受PSMA-PET/CT的患者,由两名核医学医师独立记录阳性部位,查阅多学科会议记录确定管理变化。
主要发现
- PSMA-PET/CT阳性17例(60.7%),其中仅1例为多转移(>3处),其余为前列腺切除床复发(n=2)、盆腔寡转移(n=10)或盆腔外寡转移(n=4)。
- PSMA-PET/CT导致12例(42.8%)管理改变,包括立体定向体部放疗(n=6)、挽救性放疗(n=4)和系统治疗(n=2)。
关键数值与推荐
- 极早期生化复发定义为根治性前列腺切除术后PSA<0.5 ng/ml。
- 寡转移定义为最多3个盆腔淋巴结或远处转移部位。
临床怎么用
- 对于根治性前列腺切除术后极早期生化复发(PSA<0.5 ng/ml)患者,可考虑行PSMA-PET/CT以定位病灶并指导挽救性治疗决策。
局限性
- 回顾性研究,样本量较小(28例),来自单中心三级癌症中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the availability of ultra-sensitive PSA assays, early biochemical relapse (eBCR) of prostate cancer is increasingly being detected at values much lower than the conventional threshold of 0.2 ng/ml. Accurate localisation of disease in this setting may allow treatment modification and improved outcomes, especially in patients with pelvis-confined or extra-pelvic oligometastasis (defined as up to three pelvic nodal or distant sites). We aimed to measure the detection rate of [68]Ga-PSMA-HBNED-CC (PSMA)-PET/CT and its influence on patient management in eBCR of prostate cancer following radical prostatectomy (RP). METHODS: We retrospectively identified 28 patients who underwent PSMA-PET/CT for post-RP eBCR (PSA < 0.5 ng/ml) at our tertiary care cancer centre. Two nuclear medicine physicians independently recorded the sites of PSMA-PET/CT positivity. Multidisciplinary meeting records were accessed to determine changes in management decisions following PSMA-PET/CT scans. RESULTS: The mean age of patients was 65.6 years (range: 50-76.2 years); median PSA was 0.22 ng/ml (interquartile range: 0.15 ng/ml to 0.34 ng/ml). Thirteen patients (46.4%) had received radiotherapy in the past. PSMA-PET/CT was positive in 17 patients (60.7%). Only one patient had polymetastasis (> 3 sites); the remainder either had prostatectomy bed recurrence (n = 2), pelvic oligometastasis (n = 10), or extra-pelvic oligometastasis (n = 4). PSMA-PET/CT resulted in management change in 12 patients (42.8%), involving stereotactic body radiotherapy (n = 6), salvage radiotherapy (n = 4), and systemic treatment (n = 2). CONCLUSIONS: Our findings show that PSMA-PET/CT has a high detection rate in the eBCR setting following RP, with a large proportion of patients found to have fewer than three lesions. PSMA-PET/CT may be of value in patients with early PSA failure, and impact on the choice of potentially curative salvage treatments.
引用
- Bashir U, Tree A, Mayer E, et al. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019. PMID: 30617554. doi:10.1007/s00259-018-4249-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。